As a gynecologic oncologist, Dr. Elena Ratner partners with women throughout their cancer journey, delivering comprehensive, personalized care.
Dr. Ratner practices bench-to-bedside research, examining her patient’s tumors and identifying their specific types of cancer. This allows her to design an effective, individualized treatment plan for each patient. In her lab, she also works to develop new chemotherapy and cancer drugs that effectively treat cancer and improve quality of life for her patients.
Dr. Ratner is passionate about early detection and prevention of cancers. As director of the Early Ovarian Cancer Detection Program, she helps women who are at high risk for ovarian cancer receive the appropriate screening and prophylactic options. Much of her research also focuses on identifying cancer genes and tumor markers, helping physicians understand which women are at risk for cancer. She hopes that through this important research, she and her fellow researchers can improve prevention techniques and ultimately eradicate gynecologic cancer.
Dr. Ratner helps her patients experience a high quality of life throughout treatment and into survivorship by fitting treatment around their lives and providing targeted therapies with as few side effects as possible. She works hard with each patient to preserve a sense of normalcy and to prevent cancer from taking over their lives. As the founder of the
Sexuality & Intimacy in Menopause Program, she helps survivors of cancer reconnect with their bodies using a multidisciplinary approach, including counseling, hormone therapy and other techniques.
As a result of her commitment to gynecologic cancer care, Dr. Ratner has received many awards for her teaching, research and patient care. Most recently, she was given Yale University Smilow Cancer Center Award for Clinical Excellence.
Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES.
Gynecol Oncol. 2017 Jan;144(1):77-82. doi: 10.1016/j.ygyno.2016.09.027.
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
BMC Cancer. 2016 Jul 27;16:550. doi: 10.1186/s12885-016-2598-1.
Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
Ratner ES, Zhu YL, Penketh PG, Berenblum J, Whicker ME, Huang PH, Lee Y, Ishiguro K, Zhu R, Sartorelli AC, Lin ZP.
Br J Cancer. 2016 Mar 29;114(7):777-86. doi: 10.1038/bjc.2016.54.
A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience.
Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E.
Int J Gynecol Cancer. 2015 Jun;25(5):792-7. doi: 10.1097/IGC.0000000000000431.
The clinical impact of gynecologic MRI.
Ratner ES, Staib LH, Cross SN, Raji R, Schwartz PE, McCarthy SM. AJR Am J Roentgenol. 2015 Mar;204(3):674-80. doi: 10.2214/AJR.14.12567.
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
Ishiguro K, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Zhu YL, Sartorelli AC, Rutherford TJ, Ratner ES.
Biochem Pharmacol. 2014 Oct 1;91(3):312-22. doi: 10.1016/j.bcp.2014.08.006.
Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience.
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E.
Int J Gynecol Cancer. 2014 Sep;24(7):1250-5. doi: 10.1097/IGC.0000000000000201.
Sexual function in older women after oophorectomy.
Erekson EA, Martin DK, Zhu K, Ciarleglio MM, Patel DA, Guess MK, Ratner ES. Obstet Gynecol. 2012 Oct;120(4):833-42.
Oophorectomy: the debate between ovarian conservation and elective oophorectomy.
Erekson EA, Martin DK, Ratner ES. Menopause. 2013 Jan;20(1):110-4. doi: 10.1097/gme.0b013e31825a27ab. Review.
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Ratner ES, Sartorelli AC, Lin ZP. Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230. Review.
Sexual satisfaction in the elderly female population: A special focus on women with gynecologic pathology.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner ES, Erekson EA, Minkin MJ, Foran-Tuller KA. Maturitas. 2011 Nov;70(3):210-5. doi: 10.1016/j.maturitas.2011.07.015. Review.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. Cancer Res
. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689.
MicroRNA signatures differentiate uterine cancer tumor subtypes.
Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. Gynecol Oncol. 2010 Sep;118(3):251-7. doi: 10.1016/j.ygyno.2010.05.010.
Sexuality and intimacy after gynecological cancer.
Ratner ES, Foran KA, Schwartz PE, Minkin MJ. Maturitas. 2010 May;66(1):23-6. doi: 10.1016/j.maturitas.2010.01.015. Review.
Brain metastases in epithelial ovarian and primary peritoneal carcinoma.
Ratner ES, Toy E, O'Malley DM, McAlpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Int J Gynecol Cancer. 2009 Jul;19(5):856-9. doi: 10.1111/IGC.0b013e3181a83301.